Eli Lilly announcing it will cut the prices for introductory doses of Zep found if you pay cash. This is just the latest move in the price war with Novo Nordisk that's getting more and more confusing in terms of pricing for these weight loss drugs. Joining us now to talk about it is someone who understands everything, at least in regards to this industry health.Bloomberg health reporter Madison Miller. So what do we know about Zep. LB Now it's what the five mg doses, the starter doses are going to be even c ...

Eli Lilly announcing it will cut the prices for introductory doses of Zep found if you pay cash. This is just the latest move in the price war with Novo Nordisk that's getting more and more confusing in terms of pricing for these weight loss drugs. Joining us now to talk about it is someone who understands everything, at least in regards to this industry health.Bloomberg health reporter Madison Miller. So what do we know about Zep. LB Now it's what the five mg doses, the starter doses are going to be even c ...

Core Viewpoint - The pharmaceutical companies Eli Lilly and Novo Nordisk are reducing the prices of their weight loss drugs to enhance accessibility for consumers [1]. Pricing Changes - Eli Lilly has decreased the out-of-pocket monthly price for the lowest single-dose vial of Zepbound to $299 from $349, marking a 14% reduction. The 5-milligram dose is now priced at $399, down approximately 20% from $499. Prices for the 7.5 to 15 milligram doses have been reduced to $449 from $499 [2]. - Novo Nordisk has announced a reduction in the out-of-pocket monthly price for Ozempic and Wegovy to $349 from $499. Additionally, the two lowest doses of either drug will be available for $199 per month for the first two months [3]. Market Reaction - Following the announcement of price cuts, Eli Lilly's shares fell nearly 1% in premarket trading, while Novo Nordisk's stock experienced a decline of more than 1.7% [3].

Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Dealhttps://t.co/UtY8EJHq4E https://t.co/FIr2oC6seu ...

Core Viewpoint - Eli Lilly has lowered the entry price of its weight loss drug Zepbound in response to increasing competition from Novo Nordisk, marking a significant move in the ongoing price war between the two companies in the lucrative obesity treatment market [1][2] Pricing Strategy - Starting from this week, the cash price for the lowest dose of Zepbound will be $299 per month, a reduction of approximately $50 from the previous price [1] - The price for the next higher dose will decrease to $399 per month, down about 20% from the prior cash price [1] - The highest dose remains unchanged at $499 per month [1] Competitive Landscape - The price reduction is part of a broader competitive strategy between Eli Lilly and Novo Nordisk, which has also recently lowered its cash prices for its drugs Ozempic and Wegovy [1][2] - Novo Nordisk's entry-level price for Ozempic and Wegovy is $199 for the first two months, increasing to $349 thereafter [1] Market Context - Analysts project that the global obesity treatment market will reach $100 billion by the end of this decade, highlighting the significant financial stakes involved [2] - Both companies are exploring competitive advantages, including agreements with U.S. drug benefit managers and discounts for cash-paying customers [2] Regulatory Environment - The Biden administration has announced negotiations that could lead to discounts of up to 71% for Ozempic and Wegovy for federal Medicare patients, effective in 2027 [2] - Eli Lilly and Novo Nordisk have agreed to lower their prices in the U.S. as part of a government agreement that will also apply to cash-paying customers, with changes set to take effect in 2026 [2]

Cyber Monday shopping? Drugmaker Eli Lilly & Co. is rolling out discounts of its own, slashing the cash-pay prices for starting doses of its wildly popular weight-loss shot https://t.co/DKngl3UhqW ...

Group 1: Eli Lilly & Co. - Eli Lilly is reducing the cash cost of its weight-loss drug Zepbound on its direct-to-consumer platform, with prices now ranging from $299 to $449 per month, down from $349 to $499 [2] - This price cut follows agreements made by President Donald Trump with Eli Lilly and competitor Novo Nordisk to enhance accessibility and affordability of their weight-loss drugs [2] Group 2: Disney - The Thanksgiving box office performance is expected to be one of the best in history, with an estimated $294 million in revenue over the holiday weekend [4] - Disney's "Zootopia 2" led the box office, generating approximately $156 million [4] Group 3: Airbus - European-listed shares of Airbus fell due to reports of an industrial quality issue affecting the fuselage panels of its A320-family aircraft, leading to delayed deliveries [7] - Airbus recently faced a software glitch that grounded about 6,000 of its A320-family planes over the holiday weekend [8] Group 4: Family Businesses in Memorial Products - Family businesses providing personalized memorial products are facing challenges from increasing cremation rates and tariff hikes imposed by Trump [9] - Despite tariffs, these businesses continue to import granite due to higher labor costs in the U.S. and the necessity of certain types of stone only available internationally [10]

Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies... ...

Core Insights - Eli Lilly is reducing the cash prices of its weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, to enhance accessibility for patients [1][4] - The price reduction follows a similar move by rival Novo Nordisk, which has also lowered prices for its obesity and diabetes medications [1][7] Pricing Details - Starting Monday, cash-paying patients can obtain the initial dose of Zepbound for $299 per month, down from $349, with subsequent doses priced at $399 and $449, respectively [2] - The list price of Zepbound is approximately $1,086 per month, which has been a barrier for many patients due to limited insurance coverage for weight loss drugs in the U.S. [3] Government Initiatives - The announcement aligns with recent agreements made by the Trump administration to make GLP-1 drugs more affordable and accessible, including Medicare coverage for obesity drugs for certain patients [4] - Eli Lilly's collaboration with the Trump administration focuses on reducing prices for a multi-dose pen version of Zepbound, which is pending FDA approval [5] Market Context - Direct-to-consumer sales of Zepbound account for over a third of new prescriptions, indicating a significant market presence [7] - Novo Nordisk has also reduced the prices of its drugs Wegovy and Ozempic for cash-paying patients, reflecting competitive pricing strategies in the obesity treatment market [7][8]

Group 1 - Eli Lilly (LLY) has recently achieved a trillion-dollar valuation, becoming the 11th company to do so [1] - Nvidia (NVDA) remains the top company by market valuation, followed closely by Apple (AAPL) and Alphabet (GOOGL) [1] - Other companies in the top five include Microsoft (MSFT) and Amazon.com (AMZN) [1] Group 2 - The list of companies with significant valuations also includes Broadcom (AVGO), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), Tesla (TSLA), and Berkshire Hathaway (BRKB) [1]